ArticleBMC infectious diseases2026
Systemic inflammation response index predicts short-term mortality in intensive care unit patients with bacterial bloodstream infections.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloodstream infections (BSI) in intensive care units (ICU) are associated with high mortality, requiring reliable prognostic tools. The systemic inflammatory response index (SIRI) may be a novel biomarker that may help prediction of outcomes in these patients. This study aims to evaluate the prognostic value of SIRI in predicting mortality and discharge outcomes in ICU patients with bloodstream infection (BSI).
methodsThis retrospective study included 199 adult patients diagnosed with bloodstream infections at Sakarya University Training and Research Hospital between 2018 and 2022. SIRI and other clinical parameters were calculated at the onset of BSI. The receiver operating characteristic (ROC) was used to determine the optimal cut-off SIRI value to predict the mortality. The multivariate regression analysis analyzed the correlation between mortality and SIRI.
resultsThe median SIRI (mSIRI) value at the onset of BSI was 5003. Notably, higher SIRI levels were significantly associated with an increased risk of both 14-day and 30-day mortality (p = 0.001 and p = 0.011, respectively). In the multivariate analysis, SIRI ≥ 5003 demonstrated an independent predictive value for 14-day mortality (p = 0.02). Furthermore, logistic regression analysis revealed that higher initial CRP and SIRI levels, elevated neutrophil counts, and the presence of COVID-19 or malignancy were independently associated with increased mortality risk.
conclusionOur results suggest higher SIRI levels are independently associated with the BSI and 14-day mortality. SIRI is a valid and cost-effective prognostic marker of mortality in ICU patients with bloodstream infections. Its use in clinical practice can improve risk stratification and guide therapeutic decisions. Further studies are needed to validate these results in different populations. RANDOMIZED CONTROLLED TRIAL NUMBER: Clinical trial number: not applicable. Since this study has a retrospective design, it is not possible to assign a Randomized Controlled Trial number to it.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.